The GUCA1A gene encodes a guanylate cyclase activating protein (GCAP1) that is involved in regulation of phototransduction in the vertebrate retina. We discovered a novel C312A transversion in exon 2 of the human GUCA1A gene, replacing Asn-104 (N104) in GCAP1 with Lys (K), in two affected members of a family with dominant cone dystrophy. The mutation N104K is located in the third EF-hand motif (EF3) shown previously to be instrumental in converting Ca 2+ -free GCAP1 to a GC inhibitor in the Ca 2+ -bound form. In one patient, rod ERGs were fairly stable over a 12-year-period whereas 30 Hz flicker ERG and single-flash cone ERGs declined. In both patients, double-flash ERGs showed that rod recovery from an intense test flash was significantly delayed. The EC 50 for GC stimulation shifted from $250 nM in wild-type GCAP1 to $800 nM in the GCAP1(N104K) mutant suggesting inability of the mutant to assume an inactive form under physiological conditions. The replacement of N104 by K in GCAP1 is the first naturally occurring mutation identified in the EF3 loop. The rod recovery delays observed in double-flash ERG of affected patients suggest a novel dominant-negative effect that slows GC stimulation.
Introduction
Photoreceptors, using a process termed phototransduction, receive light and generate an electrical impulse that is sent to the visual cortex (Burns & Arshavsky, 2005; Ridge, Abdulaev, Sousa, & Palczewski, 2003; Stephen, Filipek, Palczewski, & Sousa, 2008) . Key events in phototransduction are the hydrolysis of cGMP, the secondary messenger of phototransduction, and closure of cGMP-gated cation channels (Polans, Baehr, & Palczewski, 1996) . Channel closure triggers a change in free [Ca 2+ ] (Nakatani, Chen, Yau, & Koutalos, 2002; Pugh, Nikonov, & Lamb, 1999) and re-synthesis of cGMP by membrane-associated guanylate cyclases (GCs) present in rod and cone outer segments . Changes in cytoplasmic [Ca 2+ ] are monitored by GC-activating proteins (GCAPs) which are Ca 2+ -binding proteins of the calmodulin superfamily (Palczewski, Sokal, & Baehr, 2004) . Conformations of GCAPs change in response to Ca 2+ binding. In dark-adapted outer segments, free Ca 2+ is controlled by a light-insensitive NCKX and the cGMP-gated channel, and adjusts to about 250-600 nM (Woodruff et al., 2007) . Under these conditions, high affinity Ca
2+
-binding sites (EF-hands) on GCAPs are saturated, GCAPs are inactive and the GCs display a low basal activity (Gorczyca, Gray-Keller, Detwiler, & Palczewski, 1994a) . In response to light, free [Ca 2+ ] drops to less than 50 nM, Ca 2+ dissociates from Ca 2+ -binding sites, and GCAPs convert into activators accelerating cGMP synthesis roughly 8-and 10-fold.
GCAPs are N-myristoylated neuronal Ca 2+ sensors in which the acyl side chain is buried in the Ca 2+ -bound as well as the Ca 2+ -free state (Stephen, Bereta, Golczak, Palczewski, & Sousa, 2007) . A hallmark of the GCAP structure are high affinity Ca 2+ -binding sites termed EF-hands (Falke, Drake, Hazard, & Peerson, 1994; Gifford, Walsh, & Vogel, 2007; Persechini, Moncrief, & Kretsinger, 1989) consisting of a helix-loop-helix secondary structure that is able to chelate Ca 2+ ions. EF-hands also have affinity for Mg 2+ ions but the interaction is several orders of magnitude weaker (Gifford et al., 2007) . In the canonical EF-hand, the loop consists of 12 amino acids rich in acidic residues providing oxygen ligands for Ca nonfunctional, as Ca 2+ coordination is prevented by lack of acidic side chains providing oxygen for Ca 2+ coordination . The N-terminal region including EF1 has a key role in interaction with the target protein GC (Ermilov, Olshevskaya, & Dizhoor, 2001; Krylov, Niemi, Dizhoor, & Hurley, 1999; Li, Sokal, Bronson, Palczewski, & Baehr, 2001 (Otto-Bruc et al., 1997; Peshenko & Dizhoor, 2007; Rudnicka-Nawrot et al., 1998; Sokal et al., 1999) . Pathogenic mutations of residues flanking EF3 and EF4, as well as several residues of the EF4 loop of GCAP1, are associated with autosomal dominant cone dystrophy (adCD) or autosomal dominant cone-rod dystrophy (adCRD) (for review: (Baehr & Palczewski, 2007) ). Four mutations are known to affect Ca 2+ -binding of EF-hands (Y99C, I143NT, L151F, E155G) (Dizhoor, Boikov, & Olshevskaya, 1998; Jiang et al., 2005; Nishiguchi et al., 2004; Sokal et al., 1998 Sokal et al., , 2005 Wilkie et al., 2001) . The Y99C mutation is located adjacent to EF3 and I143NT adjacent to the EF4-hand motif (Nishiguchi et al., 2004) . Two mutations (E155G, L151F) are located in EF4. These mutations alter the dissociation constant and coordination of Ca 2+ to the mutant loop, and change the Ca 2+ sensitivity of GCAP1. As a result, mutant GCAPs are not fully inactivated at dark Ca 2+ levels, leading to the persistent stimulation of GC1 in the dark, elevated cGMP and Ca 2+ levels, and cell death. To date, no naturally occurring mutations affecting one of the 12 amino acids of the Ca
-binding loop of EF3 had been identified. Here, we investigated a single family with dominant cone dystrophy and identified a novel mutation in the GUCA1A gene in which Asn-104 (N104), located in EF3, is replaced by lysine. It is predicted that the N104K substitution will dramatically affect the ability of the mutant GCAP1 to inhibit GC1 in dark-adapted cone photoreceptors.
Methods

Patients and mutation identification
This study was approved by each Institutional Review Board of the University of Utah Hospitals and Clinics, and the University of Texas Southwestern Medical Center-Dallas. All subjects provided informed consent prior to participation. Some subjects underwent complete ophthalmologic examination including visual acuity measurements and fundus examinations. Blood samples from two family members (#8279 and #4940, Fig. 1 ) were collected under consignment and genomic DNA was extracted using the Puregene DNA isolation kit. Each of the four exons of GCAP1 was amplified by PCR using flanking intron-specific primers (GCAP1_exon1F: 5 0 -GGCCTGTCCATCTCAGACGT; GCAP1_ exon1R: 5 0 -CCCCAGCTGGTC AGGCTTCCAG; GCAP1_ exon2F: 5 0 -GCCTGAGGCTGGAGTGAGCG; GCAP1_ exon2R: 5 0 -CTAACCCTGGGCTCTCAGTTCC; GCAP1_exon3F: 5 0 -CCTGAGATAGGATAAGGATGG; GCAP1_exon3R: 5 0 -ACCCCACATC CATGGTGACC; GCAP1_exon4F: 5 0 -CTGGACTGCAGAAATGAACAC CCTC; GCAP1_exon4R: 5 0 -GGCGAGCTAAGCCTCTGAGTTC) and screened for mutations by denaturing high performance liquid chromatography (DHPLC; WAVE Ò System, Transgenomic, Omaha, NE). Sequence alterations were identified by direct sequencing with a CEQ Dye Terminator Cycle Sequencing Kit on Beckman-Coulter CEQ 8000 Genetic Analysis System, according to the manufacturer's instructions and using established methods (Yang et al., , 2006 .
Electroretinography
Full-field ERGs were obtained following ISCEV standards (Marmor, Holder, Seeliger, & Yamamoto, 2004) . Following pupil dilation (1% cyclopentolate hydrochloride and 2.5% phenylephrine hydrochloride) and 45 min dark-adaptation, ERGs were recorded as detailed (Birch & Fish, 1987) . PC-based custom software was used for stimulus control and timing, data acquisition, averaging, and analysis.
Inactivation kinetics were probed with the ''paired-flash" paradigm (Birch, Hood, Nusinowitz, & Pepperberg, 1995) , using a test flash of 2.4 log sc td-s. The paired-flash ERG method involves the presentation of a bright probe flash at a defined time after the test flash, and determination of the prevailing response to the test stimulus by analysis of the probe flash response. Underlying the method is the notion that the intense probe flash rapidly drives the rods to saturation and that the amplitude of the probe-generated ERG a-wave titrates the prevailing circulating current. The peak amplitude of the probe response as referred to the pre-probe baseline will approximate the circulating current at time t. From this determination of the probe response amplitude, and from the maximal amplitude exhibited by the probe-alone response, one obtains by subtraction an amplitude A that represents the rod response to the test flash at time t. That is,
where A m (t) is the probe response amplitude determined in the paired-flash trial, A mo is the amplitude of the probe-alone response, and A(t) is the amplitude at time t of the derived response to the test flash. We determined the entire time course of the response to the 2.4 log sc td-s flash in two patients (#4940; IV-3 and #8279; IV-1).
Expression and purification of recombinant human GCAP1s
Human GCAP1 coding sequence was amplified by PCR with primers including a 6-histidine tag just before the stop codon, two flanking restriction sites XbaI and XhoI, and then cloned into pFastBac-1. To generate a N104K point mutation, a site-directed mutagenesis (QuikChange Ò Site-Directed Mutagenesis Kit, Stratagene) was performed in this hGCAP1 pFastBac construct by using the following sense and antisense primer: 5 0 -GATGTAGATGGCAAAGGCTGCATT GACCGCG, 5 0 -CGCGGTCAATGCAGCCTTTGCCATCTACATC. hGCAP1 wild-type and N104K mutant plasmids were transformed into DH10Bac competent cells to generate the recombinant bacmids, and then the bacmids were transfected into High five insect cells to produce recombinant baculovirus and hGCAP1 proteins (Bac-toBac Ò Baculovirus Expression System, Invitrogen). Expression of the recombinant hGCAP1s was confirmed by Western blot analysis with GCAP1 antibody UW101. Recombinant hGCAP1 proteins were purified with Ni columns (Ni-NTA Columns, Qiagen). The purified proteins were dialyzed twice for 8-12 h against 2 L of protein buffer with glycerol (50 mM HEPES, 90 mM KCl, 10 mM NaCl, 50% v/v glycerol, pH 7.4) at 4°C. Dialysis of each 1 ml aliquot of GCAP preparation was performed using a 10 kDa MWCO Slide-A-Lyzer cassette (Pierce) in a cold room. The purity and concentration of hGCAP1 proteins were estimated by SDS-PAGE with Coomassie blue staining and Bradford's protein assay (Bio-Rad).
SDS-PAGE and limited proteolysis of hGCAP1s
SDS-PAGE in the presence and absence of Ca 2+ (1 mM Ca 2+ or 1 mM EGTA) and limited proteolysis of purified GCAP1 and GCAP1 mutants were carried out as described (Nishiguchi et al., 2004; Rudnicka-Nawrot et al., 1998) . For limited proteolysis, the recombinant hGCAP1 wild-type or mutant protein in the present or absence of Ca 2+ (1 mM Ca 2+ or 1 mM EGTA) was incubated with trypsin (at a mass ratio of 100:1) at 30°C. Proteolysis of hGCAP1 protein was stopped at various times with trypsin inhibitor (0, 5, 10, 20, 40, and 60 min) , and the products were analyzed by SDS-PAGE with Coomassie staining. 
Guanylate cyclase assay
The GC activity was assayed as described (Gorczyca, Van Hooser, & Palczewski, 1994b; Gorczyca et al., 1994a ) with minor modifications. Briefly, each 50 ll reaction mix contained 10 ll of 5X assay buffer (150 mM HEPES, 270 mM KCl, 30 mM NaCl, 50 mM MgCl 2 , 2.5 mM EGTA), 10 ll of 5 mM IBMX (3-isobuyl-1-methyl-xanthine, Sigma), 10 ll of washed cell membranes in protein buffer (50 mM HEPES, 90 mM KCl, 10 mM NaCl, pH 7.4), 10 ll of 25 lM wild-type or mutant(N104K) GCAP in protein buffer with 50% v/v glycerol, 5 ll of CaCl 2 (concentration ranging from 0.34-6 mM to obtain free Ca Following centrifugation at 16000g for 4 min, the supernatant (0.3 ml) was mixed with 3 ml of scintillation cocktail and radioactivity was measured by a scintillation counter.
Results
Human patients
The proband (IV-3; #4940) was first seen at the Retina Foundation of the Southwest in 1995 at age 33. His acuity was OD 20/200 and OS 20/80. His refraction was OD: À2.00 +3.00 Ã 095; OS: À2.00 +3.00 Ã 082. He was diagnosed with dominant cone dystrophy by the referring retinal specialist. The pedigree (Fig. 1A) , fundus appearance (Fig. 1B) , and full-field ERG ( The proband's brother (IV-1; #8279) was first seen at age 47. His acuity was OD 20/320 and OS 20/200. His refraction was OD: À5.00 +3.75 Ã 113; OS: À3.50 +2.00 Ã 077. Humphrey visual fields showed a dense central scotoma with near normal sensitivity in the peripheral retina. Visual thresholds 7°below fixation following 45 min of dark-adaptation were within the normal range.
Electroretinography
Full-field ERGs from the proband are shown in Fig. 2 . Rod responses to the ISCEV standard stimulus ( Fig. 2A) were reduced 40% in amplitude compared to the lower limit of normal, and borderline delayed in b-wave implicit time (89.6 ms vs. upper limit of normal of 88.2 ms). Similarly, mixed rod and cone combined ERGs were reduced 40% in amplitude (compared to the lower limit of normal (Fig. 2B) . Cone responses to the 30 Hz flicker (Fig. 2C) were reduced 65% in amplitude compared to the lower limit of normal. With a b-wave implicit time of 34.4 ms, these responses were only slightly delayed relative to the upper limit of normal (31.5 ms). Similarly, the single-flash cone ERG (Fig. 2D ) was 70% reduced in amplitude and borderline normal in b-wave implicit time. Over 12 years of follow-up, rod responses fluctuated somewhat in amplitude but showed no clear trend toward progression. Cone responses, on the other hand, declined progressively over the 12 years, but at a slow rate of 0.66 lV (5%) per year.
The brother of the proband (IV-1, #8279) was tested once at age 47 years. His ISCEV standard rod response was reduced in amplitude by 76%, while cone responses to 30 Hz flicker and singleflashes were reduced in amplitude by greater than 99% (results not shown). Both rod and cone responses were borderline delayed in b-wave implicit time.
Results from the paired-flash paradigm are shown in Fig. 3 for a representative normal subject (3A), the proband (3B), and his brother (3C). The trace marked PA represents the first 20 ms of the maximal, saturated rod response to a probe flash of 4.3 log sc td-s (log scotopic troland-seconds) presented singly to the darkadapted eye. When presented shortly after a just-saturating test flash of 2.4 log sc td-s, no response to the probe is detected as the photoresponse is still saturated. The a-wave first becomes evident at about 600 ms in the normal subject, and about 900 ms in the patients. As the interval between paired-flashes lengthens, the response to the probe grows in amplitude.
Full recovery functions for the proband (#4940), his brother (#8279) and the representative normal subject are shown in Fig. 4 . Relative amplitude [the ratio of A to maximum saturated amplitude (A mo )] is plotted as a function of the time (t) between the test flash and the probe flash. The best-fit curves are exponential recovery functions: A/A mo = exp[À(tÀT sat )/s], where T sat is the period of rod saturation that precedes recovery and s is a recovery time constant. Cone responses are computersubtracted to isolate the rod photoresponse. When presented singly, the probealone (PA) produces a maximal, saturated response from the rod photoreceptors. When presented shortly after a just-saturating test flash of 2.4 log sc td-s, the probe elicits no response as the photoresponse is still saturated. As the interval between paired-flashes lengthens, the response to the probe becomes evident and progressively grows in amplitude. With an interval of approximately 1500 ms, the response has fully recovered; i.e., inactivation of the photoresponse is complete. Compared to the representative normal subject (T sat = 520 ms) and a mean normal of 490.1 ± 111.2 ms (Kozma et al., 2005) , both the proband (889 ms) and his brother (802 ms) showed large delays.
Identification of the mutation in the GUCA1A gene
Mutation screening by DHPLC (denaturing high pressure liquid chromatography) and direct sequencing of amplified GUCA1A exons of patient IV:3 identified a novel C312A transversion in exon 2 (Fig. 5A ). This mutation replaced N104 in GCAP1 with Lys resulting in a novel N104K change in the GCAP1 amino acid sequences in the affected individual. No mutation was identified in exon 2 of over 200 normal controls. The N104K mutation occurs within the third EF-hand domain of GCAP1 and represents the first naturally occurring mutation in this 12-amino-acid-loop (Fig. 5B) . A mutation of a residue flanking EF3 (Y99C) disrupts the N-terminal helix of the helix-loop-helix conformation of EF3, severely affecting Ca 2+ binding at this site. Another pathogenic mutation of a flanking hydrophobic residue (I143NT) (Nishiguchi et al., 2004) was observed in EF4, emphasizing the importance of an intact N-terminal helix for Ca 2+ binding. Other mutations linked to cone dystrophy (E155G, and L151F) affect exclusively Ca 2+ coordination in EF4 Sokal et al., 2005; Wilkie et al., 2001) (Fig. 5B) .
Ca
2+
-dependent conformational changes in wild-type and mutant GCAP1 N104, the 5th amino acid residue of the EF3 loop, provides a key ligand for Ca 2+ coordination. The N104K mutation is pre- whose Ca2+/EGTA shifts are identical to WT GCAP1 . We showed previously that, in the absence of Ca 2+ , GCAP1 is readily susceptible to proteolysis by trypsin (Rudnicka-Nawrot et al., 1998; Sokal et al., 2005) , presumably by exposing positively charges residues (sites of trypsin cleavage). Exposure of GCAP1 to trypsin in the absence of Ca 2+ leads to complete digestion in less than 10 min (Fig. 6B) . Proteolysis is restricted, however, when Ca 2+ is bound to the EF-hands because cleavage sites become more inaccessible owing to conformational changes (Fig. 6C) . In contrast to wild-type GCAP1, GCAP1(N104K) is more susceptible to proteolysis even at 1 mM Ca 2+ . We conclude that the N104K mutation introduces a structural change that is irreversible even at 1 mM Ca
. showing the arrangement of the four EF-hands and the position of mutant amino acids homologous to the human sequence. The structure was drawn with Pymol software based on the 2.0 A resolution crystal structure (Stephen et al., 2007) . Amino acids mutated in autosomal dominant cone dystrophy are indicated in red. The Y99C mutation is located adjacent to the EF3-hand motif and three mutations (I143NT, E155G, L151F) have been described in EF4-hand motif Nishiguchi et al., 2004; Sokal et al., 2005; Wilkie et al., 2001) . A fifth mutation (P50L) is located between EF1 and EF2, and does not affect Ca 2+ binding . The N-terminal myristoyl side chain, buried in the N-terminal domain, is shown in purple in close proximity to the C-terminal helix.
GCAP1(N104K) stimulates GC1 less efficiently and is incompletely inactivated
We next compared the ability of GCAP1(N104K) and wild-type GCAP1 to stimulate GC1 in vitro (Fig. 7) . wild-type and mutant GCAPs were assayed for GC1 stimulation in the presence of variable amounts on GCAP1 (Fig. 7A) , as well as a function of free Ca 2+ (Fig.   7B ). The specific activity of the mutant GCAP1 is significantly reduced relative to wild-type (Fig. 7A) suggesting that the mutation affects GCAP1-GC1 interactions (see Section 4). Previous analyses of GCAP1 EF-hand loop or flanking mutations (Dizhoor et al., 1998; Nishiguchi et al., 2004; Sokal et al., 1998 Sokal et al., , 2005 Wilkie et al., 2001) showed incomplete inactivation of GC1 at physiological dark Ca ] with a peak activity at 200 nM [Ca 2+ ], dropping to about 60% at very low Ca 2+ (10 nM). With increasing free [Ca 2+ ], the mutant GCAP1 remains active at Ca 2+ levels at which wild-type GCAP1 is inactive. Consistent with other EFhand mutations, the findings indicate that mutations affecting EF3 will partially impair GC inhibition, leading to persistent stimulation in dark-adapted photoreceptors, and raising [cGMP] to toxic levels.
Discussion
Heterogeneous cone and cone-rod dystrophies (CD and CRD, respectively), inherited in a dominant, recessive, or X-linked fashion, are rare diseases characterized primarily by progressive dysfunction of the cone-mediated visual system. Major hallmarks are photophobia, reduced central visual acuity, achromatopsia, but initially preserved peripheral vision mediated by rod photoreceptors (Hamel, 2007; Simunovic & Moore, 1998) . CD and CRD are diagnosed mainly on the basis of changes in the photopic and scotopic electroretinogram, but also by fundoscopy and optical coherence tomography (Baraas et al., 2007; Jiang et al., 2005; Wissinger et al., 2008; Wolfing, Chung, Carroll, Roorda, & Williams, 2006) . The best characterized genes linked to dominant CD/CRD are GUCY2D, encoding photoreceptor guanylate cyclase 1 (retGC-1 or GC1), and GUCA1A, encoding the Ca 2+ -binding protein GCAP1, which are both expressed exclusively in photoreceptors Perrault et al., 2000) .
The phenotypes of the two patients from the GCAP1(N104K) family are comparable to other patients with CD. In young patients, the rod ERG can be normal. Both patients reported here had developed dense central scotomas, which is typical of the disease and can modestly affect the rod ERG. Nevertheless, rod function in the periphery remained normal in both patients on all visits. Normal peripheral rod function in these patients distinguishes them from patients with CRD, where rod function shows progressive decline throughout the retina (Birch, Anderson, & Fish, 1999) . The cone ERG was more severely affected than the rod ERG in both patients and showed progressive decline over 12 years of followup in one patient. Both patients showed substantial increases in T sat , the period of rod saturation that precedes recovery from an intense flash. This delayed recovery in the rod ERG photoreceptor response has been shown to be analogous to a delay in inactivation in single photoreceptor responses (Pepperberg, Birch, & Hood, 2000) . This delay presumably reflects a defect in the ability of mutant GCAP to respond to the drop in free [Ca 2+ ] following cGMP-gated channel closure.
Other photoreceptor-specific genes linked to adCD or adCRD are CRX, RIM1, PITPNM3, and UNC119 (Table 1 ). The transcription factor CRX, a factor essential for the maintenance of mammalian photoreceptors (Freund et al., 1997) , regulates the expression of several outer segment proteins such as visual pigments and arrestin. Human RIM1, a putative effector protein for rab3 proteins which are small GTPases involved in synaptic exocytosis (Johnson et al., 2003; Wang, Liu, Biederer, & Sudhof, 2002) . RIM1 is a protein localizing to the synaptic ribbon and possibly involved in regulation of glutamate release (Schoch et al., 2002) . CRD genes like those encoding a membrane-associated phosphatidylinositol transfer protein (PITPNM3), a human homolog of the D. melanogaster rdgB gene, and UNC119 encoding the retina specific gene RG4 with a possible function in synaptic transmission (Kobayashi et al., 2000) are less well characterized.
Considering the diversity of genes and mutations linked to dominant CD, mutations in the GUCA1A gene are probably the best understood in terms of disease mechanism. In these GCAP1 mutants, residues involved in Ca 2+ coordination or in stabilization of the loop structure are replaced by inappropriate amino acids lacking the desired properties. The consequence is inability of the mutant GCAP to assume an inactive conformation at physiological dark [Ca 2+ ] ($500 nM). The crystal structure of GCAP1 with bound Ca 2+ (Stephen et al., 2007) shows a molecule consisting of an N-terminal and C-terminal half, each with a pair of EF-hands, as expected from molecular modeling (e.g., Fig. 8 in (Sokal et al., 1999) ). The N-terminal half forms a hydrophobic pocket to accommodate the myristoyl group attached to Gly-2, which is also contacted by the C-terminal helix stabilizing the link between the two halves. The N-terminal region, including EF1 which does not coordinate Ca
2+
, is thought to be instrumental for interaction with GCs. Under physiological conditions, the C-terminal half containing EF3 and EF4 is likely responsible for monitoring cytoplasmic [Ca 2+ ] and triggering conformational changes that convert the inactive form into an activator. Introduction of a Trp fluorescent reporter residue flanking EF3 (Y99W) into GCAP1 and monitoring Ca 2+ binding to EF3 revealed a strong conformational change (K m $200 nM) suggesting that binding of Ca 2+ to EF3 may be instrumental in forming the GC-activator. Tyr99 is a hydrophobic amino acid that does not distort the helix N-terminal to EF3. However, replacement of Y99 by a Cys residue (Y99C), the first mutation in GCAP1 linked to dominant cone dystrophy, had adverse effects on the structure of EF3 and Ca
-binding (Dizhoor et al., 1998; Sokal et al., 1998) . N104 occupies a position in the EF3 loop that is critical for Ca 2+ coordination by providing oxygen of the amide side chain for coordination. Both Y99C and N104K likely weaken Ca 2+ coordination at EF3 under physiological conditions preventing formation of the Ca 2+ bound structure that is essential for inhibiting GC catalytic activity. The GCAP1 crystal structure implies that mutations in EF3 may distort contacts of the kinked C-terminal helix with the N-terminal helix of GCAP1. Swain et al. (1997) Column 1, chromosomal localization. Column 2, disease nomenclature according to RetNet. Column 3, online mendelian inheritance in man (OMIM) nomenclature. Column 4, gene symbol. Column 5, function of the gene product.
